Ann: Participation in Upcoming U.S. Investor Conferences, page-13

Yes, no-one puts a flag up - deal to be announced this week or big milestone about to be announced so get in early. I guess your advisor is reading the tea leaves. In the bigger picture there is no doubting that deals will be done in the mRNA space for biotechs with an innovative platform. Everyone else is running into the same problems with delivery or toxicity from high dosage rates to make up for the fact that their delivery system is inefficient. If its not delivery then its issues to do with targeting the cell type of interest or its an immunological response that either elicits inflammation or prevents re-dosing.

mRNA is looking for the right platform. If PYC have found it there will be no shortage of interest and certainly no-one will be waiting for Phase 2 data results before jumping in. Just need to pull a rabbit out of the hat in the large animal studies.